Toward a European definition for a drug shortage: a qualitative study by De Weerdt, Elfi et al.
1 
 
Towards a European definition for a drug shortage: a qualitative study 
Elfi De Weerdt1*, Steven Simoens1, Minne Casteels1, Isabelle Huys1 
1. Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and 
Pharmacological Sciences, KU Leuven, Leuven, Belgium 
Correspondence: 
Elfi De Weerdt 
Clinical pharmacology and pharmacotherapy 
Dept. of Pharmaceutical and Pharmacological Sciences 
KU Leuven 
Herestraat 49 box 521 
3000 Leuven 
Belgium 
Elfi.deweerdt@pharm.kuleuven.be  
2 
 
Abstract 
Background: Drug shortages are currently on the rise. In-depth investigation of the problem is 
necessary, however, a variety of definitions for ‘drug shortages’ are formulated in legislations, by 
different organisations, authorities and other initiatives. For international comparison, the underlying 
definition for drug shortages is important to allow appropriate interpretation of national databases and 
the results of scientific studies. The objective is to identify the different elements which should be 
considered in a uniform definition for drug shortages in the European Union and to detect the different 
conditions for reporting drug shortages. Methods: Definitions of drug shortages were searched in the 
scientific databases as well as in the grey literature. Similar topics were identified and organisations 
were contacted to formulate the reasoning underlying the definitions. Results: Over 20 different 
definitions for drug shortages were identified. A distinction is made between general definitions of 
drug shortages and definitions used for the reporting of drug shortages. Differences and similarities are 
observed in the elements within the definitions, e.g. when does a supply problem become a drug 
shortage, permanent and/or temporally shortages, the typology and time frame of a drug shortage. The 
moment a supply problem is considered as a shortage, can be defined at four levels: (i) demand side, 
(ii) supply side, (iii) delivery of a drug and (iv) availability of a drug. Permanent discontinuations of 
drugs are not always covered in definitions for drug shortages. Some definitions only consider those 
drugs used for the treatment of serious diseases or drugs for which no alternative is available. 
Different time frames were observed, varying between one day and 20 days. Conclusion: Obtaining a 
uniform definition for drug shortages is important as well as identifying which conditions are 
preferable to report drug shortages in order to facilitate international benchmarking. This paper can be 
used as a guidance to point out all the different elements which should be considered to formulate a 
uniform definition to be applied in the European Union. 
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1 Introduction 1 
Recently, drug shortages have become a common problem in European Union (EU) Member States 2 
(European Association of Hospital Pharmacists 2014). During the past decades, the awareness for drug 3 
shortages has been grown due to the observation of an increased number of drug shortages. Different 4 
stakeholders are engaged in the problem. In the first place, hospital as well as community pharmacies 5 
are affected by drug shortages. Patients are also troubled by this problem as well as medical doctors 6 
and nurses. They might be less familiar with the alternative treatment in case of a drug shortage, which 7 
can lead to medication errors (Heiskanen et al. 2014; Pharmaceutical Group of the European Union 8 
2012; European Association of Hospital Pharmacists 2014; Yurukoglu 2012). Different umbrella 9 
organisations of the pharmaceutical industry published papers on drug shortages, some of them 10 
including guidelines on how to prevent and reduce risks for shortages. These actions suggest that drug 11 
shortages are also to the detriment of the pharmaceutical companies, due to the reputational damage it 12 
may provoke (European Federation of Pharmaceutical Industries and Associations 2013; ISPE 2014; 13 
European Association of Pharmaceutical Full-line Wholesalers (GIRP) 2013). National competent 14 
authorities are also burdened with the problem of drug shortages. Due to the EU Directive 15 
2001/83/EC, national competent authorities should control the continue supply of drugs and should be 16 
warned by the suppliers of every cessation of pharmaceutical products whether this is temporally or 17 
permanently (De Weerdt et al. 2015). 18 
 19 
Until recently, studies on drug shortages were mainly found in US literature (Ventola 2011; Kaakeh et 20 
al. 2011; Fox et al. 2014; Kweder and Dill 2013; Woodcock and Wosinska 2013). These studies 21 
investigated the scope, the causes and impact of drug shortages in the US. In recent years, more 22 
research concerning drug shortages in Europe has been published, trying to gauge the scope and 23 
causes of drug shortages (Pauwels et al. 2014; Heiskanen et al. 2014; Costelloe et al. 2014; Pauwels et 24 
al. 2015). However, the results of these studies are hard to compare as different definitions of drug 25 
shortages have been used. 26 
 27 
Should a drug supply problem always be considered as a drug shortage or should it only be considered 28 
when patients have no longer access to a particular medicine? Are drug shortages taken into account 29 
when drugs cannot be delivered for only one day and thus should a time frame be considered in the 30 
definition of drug shortages? When manufacturers retract a product from the market, should it be 31 
considered as a drug shortage?  32 
 33 
The objective of this paper is to identify the essential elements which are crucial in a definition for 34 
drug shortages and to identify which conditions are preferable to be considered when reporting drug 35 
shortages in databases. In order to achieve these aims, it was important to understand the reasons why 36 
certain organisations decided to develop their own drug shortage definition.  37 
 38 
A uniform definition at EU level together with its reporting conditions will facilitate the problem of 39 
drug shortages at different levels. Firstly, international comparison will be facilitated, especially if the 40 
national databases of the reported drug shortages are publicly accessible. E.g. national competent 41 
authorities can easily control whether a drug shortage is an international or national problem. This 42 
information can also help them to find potential solutions. Secondly, the scope of drug shortages can 43 
be objectively estimated. Understanding the scale of the problem will help to take appropriate action 44 
against drug shortages by industry as well as national authorities. And thirdly, a uniform definition 45 
will also facilitate the communication between different stakeholders. 46 
2 Methodology 47 
Because the nature of the study, it was not required to seek approval from a research ethics committee. 48 
Data were analysed anonymously. 49 
 50 
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Data were collected in the scientific literature as well as in the grey literature between October the 6th 51 
2014 and April the 31th 2015. Scientific articles were identified in the following databases: 52 
MEDLINE, Embase and Web of Science. The search strategy was developed incorporating synonyms 53 
for “drug shortages” combined with “defin*”. By using an asterisk every word starting with “defin” 54 
was included. Individual search terms and MeSH search terms were used alone and in combinations. 55 
Studies published in English, French, Dutch and German were included in the paper. Additionally, the 56 
bibliography of the retrieved papers was checked for other relevant articles or studies. Grey literature, 57 
which are websites and documents of different stakeholders, was also searched for definitions of drug 58 
shortages. Some examples of possible sources which were searched for definitions are: legislations 59 
(e.g. Belgian law, EU Directives, etc.); governmental organisations (e.g. Italian Medicines Agency 60 
(AIFA), etc.), professional organisations (International Pharmaceutical Federation (FIP); European 61 
Hospital Pharmacists Associations (EAHP), etc.); patient organisations (e.g. European Public Health 62 
Alliance, etc.). The same language criteria as described above were applied to grey literature 63 
documents. 64 
 65 
Definitions were analysed according to their literary differences and similarities. Main topics as: “the 66 
level of supply”, “permanent or temporally discontinuation”, “time limit” and “typology” were 67 
identified. These topics were investigated and observed differences and similarities were subdivided. 68 
 69 
To identify the reasoning behind the wordings within the identified general definitions, the 70 
organisations and national authorities that formulated those definitions were contacted. Three main 71 
questions were asked: (i) “when should supply problems be considered as drug shortages? Should drug 72 
shortages include supply problems when patients are not affected (meaning: when patients have to 73 
switch to another (generic) medicine, they are affected)?”; (ii) “do you believe a time frame is 74 
important in the definition of a drug shortage? Please reason why”; and (iii) “Does the definition also 75 
include drugs which have been permanently discontinued? Please explain”. These questions were sent 76 
via email to different organizations (seven national and four international). Answers were obtained 77 
from four national organizations and two international organizations. Appropriate quotes were selected 78 
from the answers and were translated from Dutch to English. Deleted parts of the quotes are indicated 79 
by “…”. The coding [R1, R2, etc.] identifies the respondent. 80 
3 Results 81 
From the literature review twenty-six different definitions for drug shortages are identified (‘Wet 82 
Betreffende de Verplichte Verzekering Voor Geneeskundige Verzorging En Uitkeringen 83 
Gecoördineerd Op 14 Juli 1994’ 1994; ‘Décret N° 2012-1096 Du 28 Septembre 2012 Relatif À 84 
L’approvisionnement En Médicaments À Usage Humain’ 2015; Instituut voor Verantwoord 85 
Medicijngebruik 2012; The Italien Medicines Agency 2014; Food and Drug Administration 2011a; 86 
Government of Canada - Health Canada 2014; Australian Government - Department of Health - 87 
Therapeutic Goods Administration (TGA) 2015; ISPE 2013; European Federation of Pharmaceutical 88 
Industries and Associations 2013; Charnay-Sonnek et al. 2013; Fédération Internationale 89 
Pharmaceutique 2013; Executive Agency for Health and Consumers 2012; Fox et al. 2009; Costelloe 90 
et al. 2014; Dragic 2012; Heiskanen et al. 2014; Pauwels et al. 2015; ANSM 2014; ‘Agencia Española 91 
de Medicamentos Y Productos Sanitarios - AEMPS’ 2015; ‘BfArM - Lieferengpässe’ 2015; Federaal 92 
Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; Koninklijke Nederlandse 93 
Maatschappij ter bevordering der Pharmacie 2014; Canadian Drug Shortage Database 2015; European 94 
Medicines Agency 2013). Different sources are acknowledged, including: national laws, governmental 95 
and professional organisations and scientific articles. All definitions found are unique, with the 96 
exception that most scientific articles refer to already existing definitions of the American Society of 97 
Hospital Pharmacies (ASHP) and/or the Food and Drug Association (FDA) (Becker et al. 2013; 98 
Wiggins et al. 2014; Balkhi et al. 2013). The definitions will be divided into three categories: (i) 99 
general definitions for drug or medicine shortages, (ii) definitions specifying the conditions to report 100 
drug shortages and (iii) definitions found in articles. It occurs that in some countries more than one 101 
definition is exploited: e.g. a definition for a drug shortage (national law) and a definition for the 102 
purpose of reporting a drug shortage (federal agency) (Food and Drug Administration 2011b; Fox et 103 
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al. 2009; Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; ‘Wet 104 
Betreffende de Verplichte Verzekering Voor Geneeskundige Verzorging En Uitkeringen 105 
Gecoördineerd Op 14 Juli 1994’ 1994). 106 
 107 
The four definitions of drug shortages found in scientific articles will not be discussed in further detail, 108 
because the aim of these definitions is to clarify which shortages are covered by the scope of such 109 
paper. 110 
 111 
In total 14 general definitions for drug shortages are found, including two references of national laws 112 
(Belgium and France), five of governmental organisations, six papers of professional organisations 113 
and a definition of the European Medicines Agency (EMA) which was formulated in 2014, however at 114 
the current time, that definition is removed from the EMA website (‘Wet Betreffende de Verplichte 115 
Verzekering Voor Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op 14 Juli 1994’ 1994; 116 
‘Décret N° 2012-1096 Du 28 Septembre 2012 Relatif À L’approvisionnement En Médicaments À 117 
Usage Humain’ 2015; The Italien Medicines Agency 2014; Instituut voor Verantwoord 118 
Medicijngebruik 2012; Food and Drug Administration 2011b; Fox et al. 2009; ISPE 2013; European 119 
Federation of Pharmaceutical Industries and Associations 2013; Executive Agency for Health and 120 
Consumers 2012; Fédération Internationale Pharmaceutique 2013; Charnay-Sonnek et al. 2013; 121 
Australian Government - Department of Health - Therapeutic Goods Administration (TGA) 2015; 122 
Government of Canada - Health Canada 2014). An overview of these definitions can be found in 123 
Table 1. 124 
 125 
Seven definitions of drug shortages for reporting purposes were found on websites of (inter)national 126 
authorities; one more was obtained by contacting the Royal Dutch Pharmacists Association Farmanco 127 
(Farmanco), the Dutch reporting database. Reporting websites are mostly nationally regulated, except 128 
for the database of EMA (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; 129 
‘BfArM - Lieferengpässe’ 2015; ‘Agencia Española de Medicamentos Y Productos Sanitarios - 130 
AEMPS’ 2015; ANSM 2014; Canadian Drug Shortage Database 2015; Australian Government - 131 
Department of Health - Therapeutic Goods Administration (TGA) 2015; European Medicines Agency 132 
2013; Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014). Table 2 displays 133 
an overview of these eight definitions. 134 
 135 
Remarkable differences between the definitions, such as “when do supply problems become drug 136 
shortages”; “permanent or temporally discontinuation”; “typology” and “time frame”, will be 137 
discussed in further detail in the next subsections. 138 
3.1 When do supply problems become drug shortages? 139 
Not every supply problem immediately causes a drug shortage. In the definitions, diverse wordings are 140 
found to describe when supply problems become drug shortages. Shortages can be expressed in four 141 
different ways, specifically according to (i) the demand side (e.g. when the supply of a drug is 142 
inadequate to meet the current or projected demand), (ii) the supply side (e.g. interruption of supply), 143 
(iii) the delivery of a drug (e.g. undeliverable), and (iv) the availability of drugs (e.g. the availability of 144 
drugs to patients). Additionally drug shortages can occur at two different levels, namely (a) at 145 
pharmacies or wholesalers and (b) at consumers’ level. The different expressions will be discussed in 146 
the next paragraphs. 147 
 148 
Demand side - With respect to the demand side, the formulation: “when the supply of a drug is 149 
inadequate to meet the current or projected demand” is found in five general definitions, including the 150 
definitions of the FDA, International Society Pharmaceutical Engineering (ISPE), Australian Health 151 
Department, Health Canada as well as the definition found in the common position paper by Charnay-152 
Sonnek et al. (see Table 1) and one definition for reporting purposes, namely of the Canadian Drug 153 
Shortages Database (see Table 2) (Food and Drug Administration 2011b; Government of Canada - 154 
Health Canada 2014; Australian Government - Department of Health - Therapeutic Goods 155 
Administration (TGA) 2015; ISPE 2013; Charnay-Sonnek et al. 2013; Canadian Drug Shortage 156 
Database 2015). These wordings indirectly suggest that supply problems at pharmacy level (i.e. an 157 
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order that is not delivered) are not considered as drug shortages. As long as there is no demand for the 158 
drug which is experiencing supply problems, these organisations do not consider the situation as a 159 
drug shortage. The FDA, ISPE and the Australian Health Department complemented these wordings 160 
with “at patient/user/consumer level” (Food and Drug Administration 2011b; Australian Government - 161 
Department of Health - Therapeutic Goods Administration (TGA) 2015; ISPE 2013; Charnay-Sonnek 162 
et al. 2013). A small difference should be acknowledged between “patient level” and “user or 163 
consumer level”. The latter includes patients as well as healthy people using the drug, e.g. in 164 
experiments. 165 
 166 
Supply side - Five definitions consider drug shortages at the level of the supply side using expressions 167 
as “inadequate supply”, “interruption of supply” or “supply issue”. Three out of the five are general 168 
definitions, namely from the European Federation of Pharmaceutical Industries and Associations 169 
(EFPIA), the Dutch Institute for Rational Use of Medicines and the International Pharmaceutical 170 
Federation (FIP) (see Table 1) and additionally two reporting definitions: from the Federal Institute for 171 
Drugs and Medical Devices (BfArM) and Spanish Agency of Medicines and Medical Devices 172 
(AEMPS) (see Table 2) (Instituut voor Verantwoord Medicijngebruik 2012; European Federation of 173 
Pharmaceutical Industries and Associations 2013; Fédération Internationale Pharmaceutique 2013; 174 
‘Agencia Española de Medicamentos Y Productos Sanitarios - AEMPS’ 2015; ‘BfArM - 175 
Lieferengpässe’ 2015). These expressions do not indicate by whom, pharmacy or consumers, drug 176 
shortages should be perceived. Only the FIP indicates in the sequel of the definition that this supply 177 
issue impacts patient care (Fédération Internationale Pharmaceutique 2013). 178 
 179 
Delivery of a drug - Definitions found in the Belgian and French laws, as well as the definition 180 
formulated by the EMA in 2014, use the phrase “undeliverable” as a basis for drug shortages (see 181 
Table 1) (‘Wet Betreffende de Verplichte Verzekering Voor Geneeskundige Verzorging En 182 
Uitkeringen Gecoördineerd Op 14 Juli 1994’ 1994; ‘Décret N° 2012-1096 Du 28 Septembre 2012 183 
Relatif À L’approvisionnement En Médicaments À Usage Humain’ 2015). Again a difference is 184 
noticed regarding the specified level: the Belgian law declares a situation as a drug shortage at the 185 
level of community pharmacies, hospital pharmacies or wholesalers, while the French law and EMA 186 
specify their definitions at patient level (‘Wet Betreffende de Verplichte Verzekering Voor 187 
Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op 14 Juli 1994’ 1994; ‘Décret N° 2012-188 
1096 Du 28 Septembre 2012 Relatif À L’approvisionnement En Médicaments À Usage Humain’ 189 
2015). 190 
 191 
Availability of a drug - The Italian medicine agency (AIFA) and the Executive Agency for Health and 192 
Consumers (EAHC) define drug shortages as “the availability of drugs to patients” (see Table 1) 193 
(Executive Agency for Health and Consumers 2012; The Italien Medicines Agency 2014). This 194 
expression clarifies at which level drug shortages are considered, however it also regards access to 195 
medicines. The French National Agency for Medicines and Health Products Safety (ANSM) and the 196 
Federal Agency of Medicines and Health Products (FAMHP) use the expression of “unavailable” to 197 
specify the reporting conditions in France and Belgium (see Table 2) (Federaal Agentschap voor 198 
Geneesmiddelen en Gezondheidsproducten 2014; ANSM 2014). 199 
 200 
Considering the replies of the contacted organisations on the question: “when do supply problems 201 
become drug shortages”, different opinions were observed. Answers are very divergent and the 202 
following quotes highlight the differences between several organisations on their approach to 203 
evaluating supply problems. 204 
 205 
“All (supply) interruptions should be evaluated for their potential to contribute to a 206 
shortage.” [R1] 207 
 208 
“Supply problems should be considered as drug shortages when the pharmacist or medical 209 
doctor has to change the prescription.” [R2] 210 
 211 
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“A supply problem becomes a shortage as soon as it has consequences with regard to deliver 212 
medicines …” [R3] 213 
 214 
3.2 What about permanent discontinuation of drugs? 215 
Drug shortages can be temporally (e.g. quality problems) or permanent (e.g. withdrawal of the 216 
marketing authorisation). As discussed above, diverse wording formulations are found to express drug 217 
shortages. Still it remains unclear for all of these expressions whether they include temporally as well 218 
as permanent discontinuation. After contacting different organisations, most organisations 219 
acknowledge the enormous consequences of permanent cessation of drugs, but do not consider it as a 220 
shortage, rather as an unavailability. The following quotes illustrate the different opinions: 221 
 222 
“If a manufacturer decides to permanent discontinue a drug, there are probably alternative 223 
treatments on the market” [R2] 224 
 225 
“The definition can imply the permanent discontinuation of a drug, because it means a 226 
shortage” [R3] 227 
 228 
“The definition would include drugs that have been permanently discontinued until medical 229 
and pharmacy practice change in response to the discontinuation. Until prescribers stop 230 
prescribing a specific drug product, pharmacists will still be addressing the lack of 231 
availability, regardless of cause.” [R4] 232 
 233 
3.3 Time frame 234 
Three general definitions, namely from the Belgian and the French law and the Australian Health 235 
Department, incorporate a period during which the drug is unavailable. Only two of them indicate an 236 
exact time frame, both references are provided by national laws. The Belgian law declares “an 237 
uninterrupted period of four days” as time frame, while the French law defines drug shortages as 238 
situations where drugs are “undeliverable for three days” (‘Wet Betreffende de Verplichte Verzekering 239 
Voor Geneeskundige Verzorging En Uitkeringen Gecoördineerd Op 14 Juli 1994’ 1994; ‘Décret N° 240 
2012-1096 Du 28 Septembre 2012 Relatif À L’approvisionnement En Médicaments À Usage Humain’ 241 
2015). The Australian Health Department uses an undefined timeframe noting “not likely to meet the 242 
demand for a period of time” (Australian Government - Department of Health - Therapeutic Goods 243 
Administration (TGA) 2015). It remains unclear when the Australian government will consider supply 244 
problems as a shortage; this period can range from one day to one month or even longer. 245 
 246 
Most organizations agree that a time frame in a definition is superfluous, since it occurs that for 247 
instance in the northern part of a country a shortage is experienced while in the southern part the drug 248 
is still available.  249 
 250 
“In terms of a definition, then a time scale would seem to have little relevance.” [R1] 251 
 252 
“… as soon as a pharmacist cannot deliver a prescription drug … there is a shortage.” [R3] 253 
 254 
On the other hand, a specified time frame is often (in four of the eight definitions) used as a condition 255 
to report drug shortages (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; 256 
Government of Canada - Health Canada 2014; Koninklijke Nederlandse Maatschappij ter bevordering 257 
der Pharmacie 2014; ‘BfArM - Lieferengpässe’ 2015). Three databases will report shortages that go 258 
beyond 14 days, namely the FAMHP, Farmanco and BfArM (‘BfArM - Lieferengpässe’ 2015; 259 
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014; Federaal Agentschap 260 
voor Geneesmiddelen en Gezondheidsproducten 2014). The Canadian drug shortages database reports 261 
only drug shortages which will take longer than 20 days (Government of Canada - Health Canada 262 
2014). AEMPS uses an undefined time frame; they will report all shortages unless a rapid solution is 263 
expected (‘Agencia Española de Medicamentos Y Productos Sanitarios - AEMPS’ 2015).  264 
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 265 
3.4 Typology 266 
Including a time frame is one way to decrease the workload of (inter)national authorities when 267 
reporting drug shortages. Another way to decrease the workload of reporting drug shortages is by 268 
making a typology of the affected disease classes. This approach is only observed in reporting 269 
definitions and thus should be considered as a condition to report shortages. Databases of Germany 270 
and France will only report drugs which are intended for the treatment of life-threatening or serious 271 
diseases for which no alternative preparations are available (ANSM 2014; ‘BfArM - Lieferengpässe’ 272 
2015). In Spain, Belgium, the Netherlands and Canada no explicit typology is included in the 273 
definition and thus all drugs experiencing supply problems will be reported (‘Agencia Española de 274 
Medicamentos Y Productos Sanitarios - AEMPS’ 2015; Federaal Agentschap voor Geneesmiddelen 275 
en Gezondheidsproducten 2014; Koninklijke Nederlandse Maatschappij ter bevordering der 276 
Pharmacie 2014; Government of Canada - Health Canada 2014).  277 
4 Discussion 278 
This study provides an overview of 26 unique definitions for drug shortages as provided by two 279 
legislations, five governmental organisations, seven professional organisations, four from scientific 280 
articles, seven national reporting databases and one European reporting database (see Table 1 and 281 
Table 2) (‘Wet Betreffende de Verplichte Verzekering Voor Geneeskundige Verzorging En 282 
Uitkeringen Gecoördineerd Op 14 Juli 1994’ 1994; ‘Décret N° 2012-1096 Du 28 Septembre 2012 283 
Relatif À L’approvisionnement En Médicaments À Usage Humain’ 2015; Instituut voor Verantwoord 284 
Medicijngebruik 2012; The Italien Medicines Agency 2014; Fox et al. 2009; Food and Drug 285 
Administration 2011b; Government of Canada - Health Canada 2014; Australian Government - 286 
Department of Health - Therapeutic Goods Administration (TGA) 2015; ISPE 2014; European 287 
Federation of Pharmaceutical Industries and Associations 2013; Charnay-Sonnek et al. 2013; 288 
Fédération Internationale Pharmaceutique 2013; Executive Agency for Health and Consumers 2012; 289 
Costelloe et al. 2014; Dragic 2012; Heiskanen et al. 2014; ANSM 2014; ‘Agencia Española de 290 
Medicamentos Y Productos Sanitarios - AEMPS’ 2015; ‘BfArM - Lieferengpässe’ 2015; Federaal 291 
Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; Canadian Drug Shortage Database 292 
2015; European Medicines Agency 2013; Pauwels et al. 2015). A summary of the different elements 293 
in definitions is presented, accompanied by the conditions which are currently used to report drug 294 
shortages. The differences and similarities were compared and quotation marks with underlying 295 
reasons for a better understanding of the definitions were added. 296 
 297 
Currently two types of definitions are in circulation: general definitions to designate a drug shortage 298 
and reporting definitions to specify when to report a drug shortage. This distinction is also 299 
implemented in the results section due to essential differences between the two types of definitions. 300 
However in the future, one should aim at aggregating both definitions into one to facilitate the 301 
comparison of reporting databases and scientific studies. A general definition should be developed to 302 
designate a drug shortage and additionally one must specify uniform conditions to report shortages. 303 
The general definition together with its reporting conditions should be developed in consultation with 304 
all stakeholders which are confronted with drug shortages and should be addressed to all different 305 
stakeholders. EU policy makers are best placed to set up a stakeholder forum where the main elements 306 
of the general definition together with its reporting definition can be discussed. We propose to include 307 
the definition and the reporting conditions in an EU Directive to reach more harmonized reporting 308 
databases based on the same definition, leaving the national authorities the responsibility on the means 309 
to achieve this goal. 310 
 311 
To define this uniform definition for drug shortages, different decisions should be made. In the first 312 
place, one must determine which expression will be used to describe a drug shortage and at which 313 
level a drug shortage should be considered. At this moment four expressions are found: (i) when the 314 
supply cannot meet the demand, (ii) in case of an interruption of supply, (iii) when the drug is 315 
undeliverable, or (iv) when the drug is unavailable. Afterwards the level of drug shortages should be 316 
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determined. “At patient level” seems harder to identify in practice, while “an undelivered order” 317 
appears easier to detect. If the prices of drugs would be subjected to “free market” principles (i.e. a 318 
system in which prices for goods are set freely between vendors and consumers) a drug shortage, from 319 
an economic point of view, should be defined according to the demand side, because a shortage can 320 
only occur when the demand exceeds the supply (Simoens, Villeneuve, and Hurst 2005). 321 
 322 
Whether to include permanent discontinuations is a third issue to be considered. Permanent 323 
discontinuations are subject to other rules in case of reporting the problem, therefore it might be easier 324 
to set proper conditions for temporary shortages and permanent ones (De Weerdt et al. 2015). Still it 325 
remains important to inform patients properly when a drug will be withdrawn from the market.  326 
 327 
Incorporating a time frame in the general definition seems rather irrelevant for the following two 328 
reasons. First, only legislations contain time frames in their definitions. This can be explained by the 329 
necessity for the practical implementation of the legislations. Secondly, every country has its own 330 
policy on the delivery of drugs, therefore it might be hard to come to one time frame which can be 331 
generally applied. However, including a time frame as a reporting condition should be considered a 332 
feasible method to reduce the workload of the competent authority, especially since four of the eight 333 
references already included a specified time frame (Federaal Agentschap voor Geneesmiddelen en 334 
Gezondheidsproducten 2014; Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 335 
2014; Canadian Drug Shortage Database 2015; ‘BfArM - Lieferengpässe’ 2015). The three European 336 
references (Germany, The Netherlands and Belgium) specified that a drug should be in shortage for at 337 
least 14 days (Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten 2014; 338 
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014; ‘BfArM - 339 
Lieferengpässe’ 2015), and perhaps this can be extended to all EU Member States’ databases. 340 
 341 
Reducing the workload of competent authorities who are responsible for the drug shortages database 342 
can also be obtained by only including “drugs shortages which cause a risk for public health”. This is 343 
observed in Germany and France (‘BfArM - Lieferengpässe’ 2015; ANSM 2014). However, these 344 
restrictions will also misrepresent the size of the problem because not all shortages will be covered by 345 
the databases. 346 
 347 
Differences between the found definitions of drug shortages can be partly explained by the diversity of 348 
stakeholders. Definitions in national legislations have other purposes than the definitions of drug 349 
shortages of professional organisations. This can be explained by the different roles, responsibilities 350 
and expectations of the different stakeholders. E.g. a time frame is found in national laws and not in 351 
definitions of professional organisations, probably because national legislations consider the 352 
specificities of the local drug market. However, this does not explain the differences within a group of 353 
the same stakeholders, which may be attributed to the different missions of the organisations. E.g. the 354 
definition of the European Federation of Pharmaceutical Industries and Associations (EFPIA) is very 355 
broad and will encounter a lot more drug shortages compared to the definition of the International 356 
Pharmaceutical Federation (FIP). Although the differences between and within stakeholders, the fact 357 
that so many organisations are troubled with this problem and searching for solutions, harmonisation 358 
on the definition of drug shortages at EU level seems possible. 359 
 360 
A difference should be noted in the terms “drug shortage” and “drug unavailability”. A drug shortage 361 
is defined as “an interruption of supply chain”, while drug unavailability rather refers to “not 362 
introducing new, innovative drugs to the market” (De Weerdt et al. 2015). However, the Belgian 363 
federal agency denotes to unavailability instead of shortage and should be willing to reformulate its 364 
definitions in order to avoid confusion. 365 
 366 
Obtaining a uniform definition for drug shortages is important as well as identifying which conditions 367 
are preferable to report drug shortages in order to facilitate international comparison. This paper can 368 
be used as a guidance to point out all the different elements which should be considered to formulate a 369 
uniform definition applied in the European Union. Nevertheless, the definition should acknowledge 370 
different national legislations and opinions of diverse stakeholders. The only way to obtain this is to sit 371 
10 
 
around the table with all stakeholders involved with supply problems, which should be the next step in 372 
this investigation. 373 
 374 
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5 List of abbreviations 
AEMPS: Spanish Agency of Medicines and Medical Devices (Spain) 
AIFA: Italian Medicines Agency (Italy) 
ANSM: French National Agency for Medicines and Health Products Safety (France) 
ASHP: American Society of Hospital Pharmacies (US) 
BfArM: Federal Institute for Drugs and Medical Devices (Germany) 
EAHC: Executive Agency for Health and Consumers 
EFPIA: European Federation of Pharmaceutical Industries and Associations 
EMA: European Medicines Agency 
FAMHP: Federal Agency of Medicines and Health Products (Belgium) 
Farmanco: Royal Dutch Pharmacists Association Farmanco (the Netherlands) 
FDA: Food and Drug Association (US) 
ISPE: International Society of Pharmaceutical Engineering 
FIP: International Pharmaceutical Federation 
6 Conflicts of interest statement/Funding 
This article was supported by TEVA and the Research Foundation – Flanders (FWO). The authors do 
not have any competing interest to disclose. 
7 Authors’ contribution 
All authors participated in the design of the study. EDW performed data collection and analysis and 
drafted the manuscript. IH, SS, MC revised the manuscript critically and contributed to the 
interpretation of the data. All authors read and approved the final manuscript. 
8 Acknowledgement 
The authors wish to thank Kim Pauwels for providing information about databases of drug shortages 
in Europe, which was a source for collecting definitions. The authors also like to acknowledge the 
contribution of David Preece and Richard Price from EAHP for providing information regarding some 
definitions. 
 
  
12 
 
9 References 
‘Agencia Española de Medicamentos Y Productos Sanitarios - AEMPS.’ 2015. Accessed April 3. 
http://www.aemps.gob.es/. 
ANSM. 2014. ‘Accueil - ANSM  : Agence Nationale de Sécurité Du Médicament et Des Produits de 
Santé.’ http://www.ansm.sante.fr/. 
Australian Government - Department of Health - Therapeutic Goods Administration (TGA). 2015. 
‘Medicine Shortages Information: Questions and Answers.’ Accessed February 10. 
https://www.tga.gov.au/medicine-shortages-information-questions-and-answers. 
Balkhi, Bander, Lita Araujo-Lama, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, Sheryl L. 
Szeinbach, and Erin R. Fox. 2013. ‘Shortages of Systemic Antibiotics in the USA: How Long 
Can We Wait?’ Journal of Pharmaceutical Health Services Research 4 (1): 13–17. 
doi:10.1111/jphs.12006. 
Becker, By Daniel J, Sumit Talwar, BP Benjamin P Levy, Molly Thorn, Janna Roitman Pharmd, 
Ronald H Blum, Louis B Harrison, Michael L Grossbard, and DJ Becker. 2013. ‘Impact of 
Oncology Drug Shortages on Patient Therapy: Unplanned Treatment Changes.’ Journal of 
Oncology Practice / American Society of Clinical Oncology 9 (4). 
http://jop.ascopubs.org/content/9/4/e122.short. 
‘BfArM - Lieferengpässe.’ 2015. Accessed April 3. 
http://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Lieferengpaesse/_
node.html. 
Canadian Drug Shortage Database. 2015. ‘Drug Shortages.’ 
http://www.drugshortages.ca/drugshortagehome.asp. 
Charnay-Sonnek, Françoise, Roberto Frontini, Richard Price, Carla Hollak, David Haerry, François 
Houÿez, Oliver Timmis, Sascha Marschang, and Jurate Svarcaite. 2013. ‘Common Position 
between Patients’, Consumers, and Healthcare Professionals’ Organisations Involved in the 
Activities of the European Medicines Agency on: Supply Shortages of Medicines.’ 
Costelloe, E M, M Guinane, F Nugent, O Halley, and C Parsons. 2014. ‘An Audit of Drug Shortages 
in a Community Pharmacy Practice.’ Irish Journal of Medical Science, May. 
doi:10.1007/s11845-014-1139-7. 
De Weerdt, Elfi, Steven Simoens, Luc Hombroeckx, Minne Casteels, and Isabelle Huys. 2015. 
‘Causes of Drug Shortages in the Legal Pharmaceutical Framework.’ Regulatory Toxicology and 
Pharmacology  : RTP 71 (2): 251–58. doi:10.1016/j.yrtph.2015.01.005. 
‘Décret N° 2012-1096 Du 28 Septembre 2012 Relatif À L’approvisionnement En Médicaments À 
Usage Humain.’ 2015. Accessed January 29. 
http://legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000026426883&categorieLien=id. 
Dragic, J. 2012. ‘Analysis of Drug Shortages in a Hospital Pharmacy.’ European Journal of Hospital 
Pharmacy: Science and Practice 19 (2). British Medical Journal Publishing Group: 130–31. 
doi:10.1136/ejhpharm-2012-000074.121. 
European Association of Hospital Pharmacists. 2014. ‘Medicines Shortages in European Hospitals - 
The Evidence and Case for Action.’ 
13 
 
European Association of Pharmaceutical Full-line Wholesalers (GIRP). 2013. ‘Medicine Shortages in 
Europe and Their Impact on Patients – a Reflection Paper’, 1–8. 
European Federation of Pharmaceutical Industries and Associations. 2013. ‘EFPIA Good Practice – 
October 2013 - Reducing Risk for Drug Products Shortages’, no. October: 1–6. 
http://www.efpia.eu/uploads/Modules/Mediaroom/drugshortage_goodpractice_oct2013.pdf. 
European Medicines Agency. 2013. ‘Medicine Shortages: Shortages Catalogue.’ 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_list
ing_000376.jsp&mid=WC0b01ac05807477a6. 
Executive Agency for Health and Consumers. 2012. ‘Study on the Availability of Medicinal Products 
for Human Use.’ 
Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. 2014. ‘Onbeschikbaarheid - 
Menselijk Gebruik - FAGG.’ http://www.fagg-
afmps.be/nl/MENSELIJK_gebruik/geneesmiddelen/geneesmiddelen/distributie_aflevering/onbes
chikbaarheid/. 
Fédération Internationale Pharmaceutique. 2013. ‘Report of the International Summit on Medicines 
Shortage.’ 
Food and Drug Administration. 2011a. ‘A Review of FDA’s Approach to Medical Product Shortages.’ 
www.fda.gov/DrugShortageReport. 
———. 2011b. ‘Reports - Introduction and Background.’ Office of the Commissioner. 
http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm277745.htm. 
Fox, Erin R, Annette Birt, Ken B James, Heather Kokko, Sandra Salverson, and Donna L Soflin. 2009. 
‘ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems.’ 
American Journal of Health-System Pharmacy  : AJHP  : Official Journal of the American Society 
of Health-System Pharmacists 66 (15): 1399–1406. doi:10.2146/ajhp090026. 
Fox, Erin R, Burgunda V Sweet, and Valerie Jensen. 2014. ‘Drug Shortages: A Complex Health Care 
Crisis.’ Mayo Clinic Proceedings 89 (3): 361–73. doi:10.1016/j.mayocp.2013.11.014. 
Government of Canada - Health Canada. 2014. ‘Drug Shortages in Canada’, May. http://www.hc-
sc.gc.ca/dhp-mps/prodpharma/shortages-penuries/index-eng.php. 
Heiskanen, K, R Ahonen, P Karttunen, R Kanerva, and J Timonen. 2014. ‘Medicine Shortages - A 
Study of Community Pharmacies in Finland.’ Health Policy (Amsterdam, Netherlands), 
November. Elsevier Ireland Ltd, 1–7. doi:10.1016/j.healthpol.2014.11.001. 
Instituut voor Verantwoord Medicijngebruik. 2012. ‘Rapport Geneesmiddeltekorten.’ 
http://www.rijksoverheid.nl/documenten-en-
publicaties/rapporten/2013/02/05/geneesmiddeltekorten.html. 
ISPE. 2013. ‘Drug Shortage Survey’, 1–30. 
———. 2014. ISPE Drug Shortages Prevention Plan. 
Kaakeh, Rola, Burgunda V Sweet, Cynthia Reilly, Colleen Bush, Sherry DeLoach, Barb Higgins, 
Angela M Clark, and James Stevenson. 2011. ‘Impact of Drug Shortages on U.S. Health 
14 
 
Systems.’ American Journal of Health-System Pharmacy  : AJHP  : Official Journal of the 
American Society of Health-System Pharmacists 68 (19): 1811–19. doi:10.2146/ajhp110210. 
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. 2014. ‘Farmanco.’ 
http://www.farmanco.knmp.nl/. 
Kweder, S L, and S Dill. 2013. ‘Drug Shortages: The Cycle of Quantity and Quality.’ Clinical 
Pharmacology and Therapeutics 93 (3): 245–51. doi:10.1038/clpt.2012.235. 
Pauwels, Kim, Isabelle Huys, Minne Casteels, and Steven Simoens. 2014. ‘Drug Shortages in 
European Countries: A Trade-off between Market Attractiveness and Cost Containment?’ BMC 
Health Services Research 14 (January): 438. doi:10.1186/1472-6963-14-438. 
Pauwels, Kim, Steven Simoens, Minne Casteels, and Isabelle Huys. 2015. ‘Insights into European 
Drug Shortages: A Survey of Hospital Pharmacists.’ PloS One 10 (3): e0119322. 
doi:10.1371/journal.pone.0119322. 
Pharmaceutical Group of the European Union. 2012. ‘Medicine Shortages in European Community 
Pharmacies.’ 
http://www.apotheker.or.at/Internet/OEAK/NewsPresse.nsf/ca4d14672a08756bc125697d004f88
41/51236ff8a9e75beec1257c69003649c2/$FILE/PGEU Statement Medicine shortages 2012.pdf. 
Simoens, Steven, Mike Villeneuve, and Jeremy Hurst. 2005. ‘Tackling Nurse Shortages in OECD 
Countries.’ doi:10.1787/172102620474. 
The European Parliament and the Council of the European Union. 2011. ‘DIRECTIVE 2001/83/EC 
OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the 
Community Code Relating to Medicinal Products for Human Use.’ Vol. 174. 
The Italien Medicines Agency. 2014. ‘AIFA Agenzia Italiana Del Farmaco.’ 
http://www.agenziafarmaco.gov.it/. 
Ventola, C Lee. 2011. ‘The Drug Shortage Crisis in the United States: Causes, Impact, and 
Management Strategies.’ P & T  : A Peer-Reviewed Journal for Formulary Management 36 (11): 
740–57. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3278171&tool=pmcentrez&renderty
pe=abstract. 
‘Wet Betreffende de Verplichte Verzekering Voor Geneeskundige Verzorging En Uitkeringen 
Gecoördineerd Op 14 Juli 1994.’ 1994. 
http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=1994071438&tabl
e_name=wet. 
Wiggins, Barbara S, Jean Nappi, Christopher R Fortier, and David J Taber. 2014. ‘Cardiovascular 
Drug Shortages: Predominant Etiologies, Clinical Implications, and Management Strategies.’ The 
Annals of Pharmacotherapy, June. doi:10.1177/1060028014539142. 
Woodcock, J, and M Wosinska. 2013. ‘Economic and Technological Drivers of Generic Sterile 
Injectable Drug Shortages.’ Clinical Pharmacology and Therapeutics 93 (2): 170–76. 
doi:10.1038/clpt.2012.220. 
Yurukoglu, Ali. 2012. ‘Medicare Reimbursements and Shortages of Sterile Injectable 
Pharmaceuticals.’ 
15 
 
 
  
16 
 
10 Tables 
Table 1: Overview of the general definitions of drug shortages 
 Source Definition 
Legislations 
 Belgian law (‘Wet 
Betreffende de 
Verplichte 
Verzekering Voor 
Geneeskundige 
Verzorging En 
Uitkeringen 
Gecoördineerd Op 14 
Juli 1994’ 1994) 
On compulsory 
insurances for 
medical care 
coordinated on 14th 
July 1994 - art. 72 bis 
A drug is unavailable when enterprises which are responsible 
for the marketing of the drug are unable to deliver that drug for 
an uninterrupted period of four days to the community 
pharmacies, hospital pharmacies or wholesalers in Belgium 
 French law (‘Décret 
N° 2012-1096 Du 28 
Septembre 2012 
Relatif À 
L’approvisionnement 
En Médicaments À 
Usage Humain’ 2015) 
Decree n° 2012-1096 
the 28th of September 
2012 on the supply of 
medicines for human 
use 
A supply disruption is the inability for a dispensary pharmacy 
or internal use pharmacy dispensing a drug to a patient within 
72 hours or within a shorter time depending on the 
compatibility problems with the continued treatment of the 
patient 
Governmental organisations 
 Dutch Institute for 
Rational Use of 
Medicine (Instituut 
voor Verantwoord 
Medicijngebruik 
2012) 
The (temporally) not or inadequate supply of a registered 
pharmaceutical 
 Italian Medicines 
Agency (AIFA) (The 
Italien Medicines 
Agency 2014) 
When a medicinal product is not available or commercially 
unavailable all over the country and the market authorisation 
holder does not assure appropriate and continued supply to 
meet the patients’ needs 
 European Medicines 
Agency (EMA) 
When the delivery of a medicine cannot comply to the needs of 
the patients, whether this is local, national or international 
 Food and Drug 
Agency (FDA) (Food 
and Drug 
Administration 
A situation in which the total supply of all clinical 
interchangeable versions of a FDA-regulated drug is 
inadequate to meet the current or projected demand at the 
17 
 
2011b) patient level 
 Health Canada 
(Government of 
Canada - Health 
Canada 2014) 
A drug shortage is a situation when a manufacturer or importer 
of a drug cannot meet actual or projected demand. Drug 
shortages can include temporary disruptions or permanent 
discontinuances in the production and supply of a drug 
 Australian Ministry of 
Health (Australian 
Government - 
Department of Health 
- Therapeutic Goods 
Administration (TGA) 
2015) 
A medicine shortage occurs when the supply of a medicine is 
not likely to meet the normal or projected consumer demand 
for the medicine within Australia for a period of time 
Professional organisations 
 International Society 
of Pharmaceutical 
Engineering (ISPE) 
(ISPE 2013) 
A situation in which the total supply of an approved (by the 
appropriate Health Authority) drug is inadequate to meet the 
current or projected demand at the user level 
 European Federation 
of Pharmaceutical 
Industries and 
Associations (EFPIA) 
(European Federation 
of Pharmaceutical 
Industries and 
Associations 2013) 
A potential drug shortage is defined as: the occurrence of 
internal or external situations (single or in a combination of 
both), which result in an interruption of supplies of a medicinal 
product, if not properly addressed and controlled 
 Common position 
paper (Charnay-
Sonnek et al.) 
(Charnay-Sonnek et 
al. 2013) 
A situation in which the total supply of an authorised medicine 
or of a medicine used on a compassionate basis is inadequate 
to meet the current or projected demand at the patient level. 
The shortage may be local, national, European or international 
 International 
Pharmaceutical 
Federation (FIP) 
(Fédération 
Internationale 
Pharmaceutique 2013) 
A medicine shortage can be defined as a drug supply issue 
requiring a change. It impacts patient care and requires the use 
of an alternative agent 
 Executive Agency for 
Health and 
Consumers (EAHC) 
(Executive Agency 
for Health and 
Consumers 2012) 
The availability to patients of medicinal products in a 
pharmacy setting 
 American Society of 
Hospital Pharmacies 
(ASHP) (Fox et al. 
2009) 
A supply issue that affects how the pharmacy prepares or 
dispenses a drug product or influences patient care when 
prescribers must use an alternative agent 
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Articles 
 Costelloe, et al. 
(Costelloe et al. 2014) 
A drug shortage was defined as the inability to purchase a 
particular drug from wholesalers on a particular day 
 Dragic (Dragic 2012) Drug shortage as every delay in monthly drug supply 
 Heiskanen, et al. 
(Heiskanen et al. 
2014) 
A drug supply issue requiring a change that impacts patient 
care and requires the use of an alternative agent 
 Pauwels et al. 
(Pauwels et al. 2015) 
A shortcoming in the supply of a medicinal product that affects 
the patient’s ability to access the required treatment in due 
time 
 
Table 2: Overview of the reporting definitions of drug shortages 
 Source Definition 
National 
 French National 
Agency for Medicines 
and Health Products 
Safety (ANSM) 
(ANSM 2014) 
Drugs for which unavailability cause a risk for public health and 
have no therapeutic alternative 
 Spanish Agency of 
Medicines and 
Medical Devices 
(AEMPS) (‘Agencia 
Española de 
Medicamentos Y 
Productos Sanitarios - 
AEMPS’ 2015) 
All drugs which experience supply problems are reported, 
except for those for which a rapid solution is expected 
 German Federal 
Institute for Drugs and 
Medical Devices 
(BfArM) (‘BfArM - 
Lieferengpässe’ 2015) 
A supply shortage is expected to go beyond two weeks 
interruption extradition to the usual extent or a significantly 
increased demand that cannot be adequately met. Only supply 
shortages of drugs listed, where special information needs of 
professionals are required. Currently, this is for prescription 
drugs that are intended primarily for the treatment of life-
threatening or serious diseases for which no alternative 
preparations are available 
 Belgian Federal 
Agency of Medicines 
and Health Products 
(FAMHP) (Federaal 
Agentschap voor 
Geneesmiddelen en 
Gezondheidsproducten 
2014) 
Holders of the market authorisation should notify the Belgian 
Federal Agency of Medicines and Health Products (FAMHP) 
when a drug will be unavailable for a time period longer than 14 
days 
 Royal Dutch 
Pharmacists 
Association Farmanco 
(Farmanco) 
All supply problems of drugs are reported if it is expected that 
the drug will be undeliverable for a time period longer than 14 
days 
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(Koninklijke 
Nederlandse 
Maatschappij ter 
bevordering der 
Pharmacie 2014) 
 Canadian Drug 
Shortage Databank 
(Canadian Drug 
Shortage Database 
2015) 
As soon as a market authorization holder knows that it will take 
longer than 20 days to supply a drug to meet expected patient 
volumes on an ongoing basis, they will report this as a shortage 
on the communications platform. It is understood that the 
inability of a patient to receive their prescribed medicines at the 
first attempt to fill a prescription may not constitute a drug 
being in 'shortage', as the drug may be available in other 
pharmacies or within the wholesale or distribution network (i.e. 
pharmacy supply chain), usually within a few days 
 Australian Medicine 
Shortages Information 
Initiative (Australian 
Government - 
Department of Health 
- Therapeutic Goods 
Administration (TGA) 
2015) 
This information is based on the voluntary notification by 
sponsors in accordance with the agreed Protocol 
European 
 European Medicines 
Agency (EMA) 
(European Medicines 
Agency 2013) 
Medicines shortages that affect or are likely to affect more than 
one EU MS, where the EMA has assessed the shortage and 
provided recommendations to patients and healthcare 
professionals across the EU 
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